Gardens Medical Center Inc

CLIA Laboratory Citation Details

2
Total Citations
6
Total Deficiencyies
5
Unique D-Tags
CMS Certification Number 05D1076583
Address 7218 Garfield Ave, Bell Gardens, CA, 90201
City Bell Gardens
State CA
Zip Code90201
Phone(562) 927-1111

Citation History (2 surveys)

Survey - November 27, 2019

Survey Type: Standard

Survey Event ID: 6NNA11

Deficiency Tags: D2020 D6016

Summary:

Summary Statement of Deficiencies D2020 BACTERIOLOGY CFR(s): 493.823(a) Failure to attain an overall testing event score of at least 80 percent is unsatisfactory performance. This STANDARD is not met as evidenced by: Based on review of the laboratory proficiency testing (PT) result reports by American Association of Bioanalysts (AAB) PT provider, and interview with the laboratory testing personnel, it was determined that the laboratory failed to attain an overall testing even score of at least 80 percent was unsatisfactory performance. the findings include: a. The laboratory performed CT/GC (Chlamydia/Gonorrhoeae) using BD Probetec ET procedures. b. The laboratory enrolled the proficiency testing with AAB to ensure and verify the accuracy of the testing system annually to meet the CLIA requirements. c. The laboratory attained a score of 0 % in the 3rd 2018 AAB PT event, which was unsatisfactory performance. d. The laboratory performed CT/GC in approximately 80 patient samples monthly. e. The laboratory affirmed (11/27/2019 @11:45 am) that the laboratory attained a score of 0 % in the 3rd 2018 AAB PT event, which was unsatisfactory performance. D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- This STANDARD is not met as evidenced by: Based on review of the laboratory AAB PT test result reports, and interview with the laboratory testing personnel, it was determined that the laboratory director failed to ensure the proficiency testing samples were tested as required in the rules and regulations and to be compliance with CLIA. The findings included: a. The laboratory performed CT/GC using BD Probetek ET and enrolled its PT with AAB PT provider. b. The laboratory attained a score of 0 % in the 3rd 2018 AAB PT event, see D-2020. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 9, 2019

Survey Type: Special

Survey Event ID: MX8G11

Deficiency Tags: D2074 D6016 D2016 D6000

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on desk review of CMS proficiency testing (PT) records (i.e. CMS CASPER Reports 0155D entitled, "Individual Laboratory Profile" and CMS CASPER Report 0153D entitled, "Unsuccessful (2 of 3) Report"), it was determined that the laboratory failed to successfully participate in a PT program approved by CMS for each analyte or test in which the laboratory is certified under CLIA. The findings included: The laboratory failed to achieve overall Syphilis Serology satisfactory performance for two out of three consecutive testing events constituting unsuccessful PT performance. (See D2074) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D2074 SYPHILIS SEROLOGY CFR(s): 493.835(e) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on desk review of CMS PT records (CMS CASPER Report 0155D and 0153D, it was determined that the laboratory failed to achieve an overall testing event score of satisfactory performance for two out of three consecutive testing events which is "initial" (first) unsuccessful performance. The findings include: a. The laboratory failed to maintain successful performance with the PT program by failing to obtain subspeciality score of 80% of acceptable responses in two out of three consecutive PT events for the subspeciality of Syphilis Serology (analyte: Rapid Plasma Reagin (RPR), as follows: 2018 Q1 2018 Q3 RPR 60% 0% Q1 = First Testing Event Q3 = Third Testing Event b. Failure to achieve overall satisfactory performance in two out of three consecutive PT resulted in an initial unsuccessful performance for the subspeciality, Syphilis Serology (test: RPR). D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on the severity of the deficiencies cited herein, the Condition: Laboratories Performing Moderate Complexity Testing: Laboratory director was not met. The laboratory director, moderate complexity testing, failed to ensure that PT samples were tested as required under Subpart H of this part. (See D6016) D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of CMS PT records, it was determined the laboratory director, moderate complexity testing, failed to ensure that PT samples were tested as required under subpart H. of this part. The findings included: For the subspecialty, Syphilis Serology (test: RPR), the laboratory repeatedly failed to achieve satisfactory performance in two out of three consecutive testing events, resulting in unsuccessful PT performance. (See D2016 and D2074) -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access